TBP.V - Tetra Bio-Pharma Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.3200
+0.0350 (+12.28%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.2850
Open0.2850
Bid0.3150 x 0
Ask0.3250 x 0
Day's Range0.2800 - 0.3300
52 Week Range0.1700 - 0.7300
Volume1,936,347
Avg. Volume1,288,225
Market Cap78.871M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-0.0810
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions
    CNW Group

    Tetra Offers Pro-Bono Regulatory and Quality Assurance Expertise to Companies Developing COVID-19 Solutions

    OTTAWA , April 8, 2020 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development has joined the battle to fight the novel COVID-19 virus. The Company will mobilize its expertise in regulatory affairs and quality assurance to support Canadian businesses seeking Health Canada approval for specific products used to mitigate the ongoing COVID-19 pandemic. This week Tetra Bio-Pharma submitted a Drug Information Number (DIN) application to Health Canada on behalf of a Canadian company ready to produce a hospital, institutional grade hard surface disinfectant.

  • GlobeNewswire

    Tetra Biopharma Confirms Type B Meeting Date With FDA Regarding HCC011

    Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that the U.S. Food & Drug Administration ("FDA") has granted the Company’s request for a Type B meeting related to its proposed clinical program and overall premarketing requirements for the Company’s product HCC011 with Orphan Drug Designation. This meeting has been scheduled for May 29, 2020.

  • GlobeNewswire

    Tetra Bio-Pharma Maps Out Cannabinoid Metabolites in Humans Following Inhalation of QIXLEEF

    Bioanalytical methods developed and validated for its clinical trials. Tetra initiates study to quantify phytocannabinoid metabolites and precursors and minor phytocannabinoids in human plasma. OTTAWA, April 02, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the launch of a study to determine the levels of cannabinoid metabolites (e.g., 7-COOH-CBD), cannabinoid precursors (e.g., CBGA) and minor cannabinoids (e.g., CBN) in the plasma of humans.

  • CNW Group

    Tetra Bio Pharma Announces Filing of Final Base Shelf Prospectus for up to $50 Million of Securities

    OTTAWA , April 1, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TBP.V) (TBPMF) announced today that it has filed a final short form base shelf prospectus with the securities commissions in each of the provinces of Canada . The base shelf prospectus will allow Tetra and certain of its security holders to qualify the distribution by way of prospectus of up to $50,000,000 of common shares, warrants, units, debt securities, subscription receipts, or any combination thereof, from time to time during the 25-month period that the shelf prospectus is effective.

  • GlobeNewswire

    Tetra Bio-Pharma Announces Filing of Restated Financial Statements and MD&A

    Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TBP.V) (TBPMF), announced today it has filed an amended and restated management’s discussion and analysis for the financial year ended November 30, 2019 ("Restated MD&A"), which is available on SEDAR under the Corporation's profile. The board of directors of the Corporation, based on the recommendation of the audit committee in consultation with the management of the Corporation, has determined that the Corporation’s previously filed management’s discussion and analysis for the for the financial year ended November 30, 2019 ("Previously Filed MD&A") needed to be restated to incorporate disclosure on the COVID-19 pandemic and its impact on the general business of Tetra. The Previously Filed MD&A was originally filed by the Corporation on SEDAR on March 25, 2020.

  • GlobeNewswire

    Tetra Biopharma Survey Validates Primary Endpoint of SERENITY© Clinical Trial

    Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced the results of a survey conducted among US and Canadian patients and physicians which validated the primary endpoint of the SERENITY© pivotal trial. Fifty to 80% of cancer patients experience cachexia during their disease1 Cachexia is defined as “multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment”2.

  • GlobeNewswire

    Tetra Bio-Pharma Provides Management Update on COVID-19

    Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, today would like to announce that it has ensured that all of its employees work under conditions that comply with federal and provincial public health recommendations. Additionally, following the completion of its $17.8 M financing in February and early March, the Company is in a good position to maintain its drug development programs. Regulatory activities have not slowed down despite the COVID-19 crisis.

  • GlobeNewswire

    Tetra Bio-Pharma Engages Alpha Bronze LLC as investor relations and public relations firm

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has engaged Alpha Bronze LLC., by its principal, Mr. Pascal Nigen, an investor relations, management consulting and financial communications firm to implement and execute a comprehensive investor relations and communications program.

  • CNW Group

    Tetra Bio-Pharma Announces Exercise of Over-Allotment Option in Connection with Bought Deal Financing

    OTTAWA, March 5, 2020 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSXV:TBP.V - News) (OTCQB:TBPMF - News), is pleased to announce that, in connection with its previously announced short form prospectus offering (the "Offering") of units of the Corporation (the "Units") for aggregate gross proceeds of $15,500,009, Echelon Wealth Partners Inc. ("Echelon"), who acted as sole underwriter and sole book runner in connection with the Offering, has exercised its over-allotment option in full, and an additional 4,386,795 Units were issued today representing additional gross proceeds of $2,325,001.35. Each Unit consists of one common share of the Corporation (each, a "Common Share") and one common share purchase warrant (each, a "Warrant"), with each Warrant entitling the holder thereof to purchase one Common Share at a price of $0.75 until February 13, 2023.

  • GlobeNewswire

    Tetra Bio-Pharma Enters into Co-Development Agreement with MAKScientific

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with MAKScientific. This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties. In the long term, this agreement secures patented new drug candidates for Tetra to develop after Caumz and QIXLEEF receive marketing approval.

  • GlobeNewswire

    Tetra Bio-Pharma Provides Additional Information on CAUMZ Following Type B Meeting with USA FDA

    505(b)(2) NDA pathway provides significant cost savings. OTTAWA, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide additional information on the drug development program for CAUMZ™ following the previously announced Type B meeting with the US Food and Drug Administration (FDA). The first indication for CAUMZ™ will be the treatment of cancer cachexia patients.

  • GlobeNewswire

    Tetra Bio-Pharma Provides Additional Information on QIXLEEF Following Letter of Advice & Type B Meeting with USA FDA

    QIXLEEF global market is expanded to include noncancer pain indications. Scientific approach to quality control of QIXLEEF validated by FDA. OTTAWA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to provide additional information on the drug development program for QIXLEEF™ following the previously announced Letter of Advice and Type B meeting with the US Food and Drug Administration (FDA).

  • GlobeNewswire

    Tetra Bio-Pharma Initiates a Proof of Concept Clinical Trial for its Ophthalmic Drug in Dogs

    Tetra Bio-Pharma Inc., (“Tetra” or the “Company”) a leader in cannabinoid-derived drug discovery and development (TSX VENTURE:TBP) (TBPMF) today announced the initiation of its clinical trial for its synthetic cannabinoid therapy (PPP003v) for the treatment of ophthalmic eye pain in the veterinary setting. On February 8th 2020, Tetra Bio-Pharma, in partnership with a veterinary ophthalmology team, initiated recruitment of an in-life phase proof of concept clinical trial in companion dogs with complications of indolent corneal ulcers, with the first dog to be treated on February 21, 2020.

  • GlobeNewswire

    Tetra Bio-Pharma Appoints Sylvain Chrétien as President

    Tetra Bio Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF) a leader in cannabinoid-derived drug discovery and development, is pleased to announce the appointment of Sylvain Chrétien as President of Tetra Bio-Pharma Inc. Mr. Chrétien will report directly to Guy Chamberland, CEO of Tetra.

  • GlobeNewswire

    Tetra Bio-Pharma Enters into Manufacturing Agreement with Vitiprints LLC for CAUMZ™ and HCC011

    Tetra Bio Pharma Inc. (“Tetra” or the “Company”) (TBP.V) (TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced it has signed a definitive manufacturing agreement with Vitiprints LLC, for the commercial scale production of CAUMZ™ and HCC011. This agreement will further protect CAUMZ™ and HCC011 with four additional patents on manufacturing know-how. VITIPRINTS has developed a proprietary and patented manufacturing system, which can be used by Tetra to manufacture its CAUMZ™ drug on commercial scale.

  • CNW Group

    Tetra Bio-Pharma Announces Closing of Bought Deal Financing

    OTTAWA, Feb. 13, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Corporation") (TSXV:TBP.V - News) (OTCQB:TBPMF - News), is pleased to announce it has closed its short form prospectus offering, on a bought deal basis. A total of 29,245,300 units (the "Units") of the Corporation were sold at a price of $0.53 per Unit, for aggregate gross proceeds of $15,500,009 (the "Offering"). Each Warrant entitles the holder thereof to purchase one common share of the Corporation at a price of $0.75 until February 13, 2023.

  • CNW Group

    IIROC Trading Resumption - TBP

    VANCOUVER , Feb. 3, 2020 /CNW/ - Trading resumes in: Company: Tetra Bio-Pharma Inc. TSX-Venture Symbol: TBP (All Issues) Resumption (ET): 9:30 AM IIROC can make a decision to impose a temporary suspension ...

  • CNW Group

    Tetra Bio-Pharma Announces CAUMZ Program Update AND Expansion of Market Potential Following Type B Meeting with USA FDA

    FDA conditions met for Fast Track designation – patient population has a serious condition with significant morbidity. Qualified for Accelerated Approval regulatory program – Tetra confirms Patient-Reported Outcome (PRO) instrument is a validated surrogate endpoint. FDA guidance allows expansion into a larger cancer therapeutics market for CAUMZ and avoids direct competition with QIXLEEF.

  • CNW Group

    Tetra Bio-Pharma Receives Favorable Response Following Type B Meeting with USA FDA for CAUMZ™

    OTTAWA, Jan. 31, 2020 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP.V - News) (OTCQB:TBPMF - News), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has received a favorable letter from the United States Food and Drug Administration ("FDA") with respect to CAUMZ™. This follows the Company's previously announced Type B meeting with the FDA for CAUMZ™. The Company will be issuing a news release on Monday, February 3rd, explaining the decisions.